COVID-19 大流行对接受新辅助治疗的手术乳腺癌患者的影响：一项多中心研究。

Impact of COVID-19 Pandemic on Surgical Breast Cancer Patients Undergoing Neoadjuvant Therapy: A Multicentric Study.

机构信息

Breast Unit, Department of Surgical Science, Policlinico Tor Vergata University, Rome, Italy.

Breast Unit, Department of Surgical Science, Policlinico Tor Vergata University, Rome, Italy;

出版信息

Anticancer Res. 2021 Sep;41(9):4535-4542. doi: 10.21873/anticanres.15265.

DOI:10.21873/anticanres.15265

PMID:34475080

Abstract

BACKGROUND/AIM: Due to the SARS-CoV-2 pandemic, many scientific committees proposed neoadjuvant therapy (NACT) bridging treatment as a novel strategy and indication. The aim of the study was to evaluate the impact of COVID-19 pandemic on breast cancer patients undergoing NACT.

PATIENTS AND METHODS

All breast cancer patients referred to two Breast Units during COVID-19-pandemic were enrolled.

RESULTS

Out of 814 patients, 43(5.3%) were enrolled in the COVID-19-group and compared with 94 (7.9%) similar Pre-COVID-19 patients. We observed a reduction in the number of patients undergoing NACT, p=0.0019. No difference was reported in terms of clinical presentation, indications, and tumor response. In contrast, a higher number of vascular adverse events was reported (6.9% vs. 0% p=0.029). Immediate breast cancer reconstructions following invasive surgery suffered a significant slowdown (5.9% vs. 47.7%, p=0.019).

CONCLUSION

COVID-19 caused a reduction in the number of patients undergoing NACT, with no changes in terms of indications, clinical presentation, and tumor response. Furthermore, there was an increased incidence of vascular events.

摘要

背景/目的：由于 SARS-CoV-2 大流行，许多科学委员会提出新辅助治疗（NACT）桥接治疗作为一种新的策略和适应证。本研究旨在评估 COVID-19 大流行对接受 NACT 的乳腺癌患者的影响。

患者和方法

在 COVID-19 大流行期间，将所有转至两个乳腺专科的乳腺癌患者纳入研究。

结果

814 例患者中，43 例（5.3%）被纳入 COVID-19 组，与 94 例（7.9%）类似的 COVID-19 前患者进行比较。我们观察到接受 NACT 的患者数量减少，p=0.0019。在临床表现、适应证和肿瘤反应方面没有差异。相比之下，报道了更多的血管不良事件（6.9% vs. 0%，p=0.029）。浸润性手术后即刻乳房重建明显放缓（5.9% vs. 47.7%，p=0.019）。